Ophthalmology. Retina最新文献

{"title":"Standardization of OCT Angiography Nomenclature in Retinal Vascular Diseases","authors":"Marion R. Munk MD, PhD ,&nbsp;Ferhat Turgut MD ,&nbsp;Livia Faes MD ,&nbsp;Damian Jaggi MD ,&nbsp;K. Bailey Freund MD ,&nbsp;Srinivas R. Sadda MD ,&nbsp;Tunde Peto MD ,&nbsp;Ruikang K. Wang PhD ,&nbsp;Michael Pircher PhD ,&nbsp;Christine A. Curcio PhD ,&nbsp;Jennifer Sun MD ,&nbsp;Amir H. Kashani MD, PhD","doi":"10.1016/j.oret.2025.01.015","DOIUrl":"10.1016/j.oret.2025.01.015","url":null,"abstract":"<div><h3>Objective</h3><div>To develop a consensus nomenclature for OCT angiography (OCTA) findings in retinal vascular diseases (RVDs).</div></div><div><h3>Design</h3><div>Expert consensus using standardized online surveys with modified Likert scale.</div></div><div><h3>Participants</h3><div>Retinal vascular disease imaging experts, OCT biomedical engineers, and the members of the International Retinal Imaging Society (IntRIS)</div></div><div><h3>Methods</h3><div>A PubMed literature review identified quantitative and qualitative terms forming the basis for a consensus-building process using a modified Delphi method. Agreement levels were categorized as “Accepted” (median ≥6), “Considerable Consensus” (median, 6–7; interquartile range [IQR] ≤3), “Strong Consensus” (median ≥8; IQR ≤2), and “Refined Strong Consensus” (median ≥8, IQR ≤2, with ≥70% of responses in the 8–10 range).</div><div>A multidisciplinary expert panel refined the terminology through 3 survey rounds, leading to a final survey conducted by IntRIS members.</div></div><div><h3>Main Outcome Measures</h3><div>Consensus on OCTA nomenclature in RVD.</div></div><div><h3>Results</h3><div>The literature review identified 58 relevant papers, yielding 51 quantitative and 108 qualitative terms. A series of 3 surveys was used to refine the nomenclature framework for describing OCTA findings. The selected framework includes a generic term (“OCTA signal”), adjective terms (“presence/absence,” “decreased/increased,” “normal/abnormal”), and descriptive/etiologic terms (“of unknown cause,” “due to blockage,” “due to non-perfusion”).</div><div>In the final survey among 44 IntRIS members, the framework achieved strong consensus for overall acceptance (median, 8.0; IQR, 7.0–9.0). The term “OCTA signal” met refined strong consensus criteria (median, 8.0; IQR, 8.0–9.0, with ≥70% of responses in the 8–10 range). Adjective terms, including “absence/presence” and “increased/decreased,” were also rated with strong consensus (median, 8.0; IQR, 7.0–9.0). Similarly, descriptive/etiologic terms achieved strong consensus (median, 8.0; IQR, 7.0–9.0).</div><div>Adoption of the framework for clinical practice and scientific reporting was rated with strong consensus (clinical: median, 8.0; IQR, 7.0–9.0; scientific: median, 9.0; IQR, 8.5–10.0).</div></div><div><h3>Conclusions</h3><div>This study establishes a strong consensus framework for reporting OCTA findings in RVD for clinical and scientific contexts.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages 645-654"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular Inflammation after Aflibercept Prefilled Syringe and Vial Injections","authors":"David M. Brown MD ,&nbsp;Rachel E. Sobel DrPH ,&nbsp;Kiliana Suzart-Woischnik MD, MPH ,&nbsp;Nick Boucher BSc ,&nbsp;Julius Asubonteng PhD ,&nbsp;Hadi Moini PhD ,&nbsp;Nitika Aggarwal BSc ,&nbsp;Suzanne Green PhD ,&nbsp;Angelika Manthripragada PhD, MPH","doi":"10.1016/j.oret.2025.03.002","DOIUrl":"10.1016/j.oret.2025.03.002","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages 712-715"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration","authors":"Nathan C. Steinle MD ,&nbsp;April J. McCullough MD ,&nbsp;Fabiana Q. Silva MD ,&nbsp;Weiming Du MA ,&nbsp;Hadi Moini PhD ,&nbsp;Rishi P. Singh MD","doi":"10.1016/j.oret.2024.12.018","DOIUrl":"10.1016/j.oret.2024.12.018","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the impact of total duration of intraretinal fluid (IRF) exposure on visual acuity and vision-related quality of life in patients with neovascular age-related macular degeneration (nAMD).</div></div><div><h3>Design</h3><div>A post hoc analysis of integrated data from the VIEW 1 and VIEW 2 trials.</div></div><div><h3>Participants</h3><div>Patients with nAMD.</div></div><div><h3>Methods</h3><div>Patients receiving intravitreal ranibizumab 0.5 mg every 4 weeks (Rq4) or intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4) or 2 mg every 8 weeks (2q8) were evaluated. Data were pooled across treatment groups, and the duration of IRF exposure was assessed by quartiles (first quartile [Q1]: ≤2 weeks; second quartile [Q2]: 3 to ≤8 weeks; third quartile [Q3]: 9 to ≤18 weeks; fourth quartile [Q4]: &gt;18 weeks). Changes from baseline in visual acuity and vision-related quality of life were evaluated by quartiles of duration of IRF exposure in the pooled treatment group and each treatment group.</div></div><div><h3>Main Outcome Measures</h3><div>Mean changes from baseline in best-corrected visual acuity (BCVA) and improvement in vision-related quality of life as assessed via National Eye Institute Visual Function Questionnaire-25 (VFQ-25) composite and subscale scores at week 52.</div></div><div><h3>Results</h3><div>A total of 1804 patients were evaluated. In the pooled analysis, mean BCVA gains from baseline at week 52 for Q1, Q2, Q3, and Q4 were +10.9, +10.1, +9.4, and +6.6 letters, respectively (Least squares mean difference Q4–Q1 [95% confidence interval]; −4.3 [−6.1, −2.5]). Mean changes from baseline to week 52 in VFQ-25 composite score for Q1, Q2, Q3, and Q4 were +5.9, +6.6, +6.1, and +4.0 points, respectively (−1.9 [−3.6, −0.2]). A similar trend was observed across VFQ-25 subscales, with patients in Q4 generally experiencing less improvement versus Q1. When BCVA gains were assessed by quartiles of duration of IRF exposure within each treatment group, mean BCVA gains for Q1, Q2, Q3, and Q4 were +11.0, +11.1, +9.3, and +5.8 letters for Rq4 (nominal <em>P</em> &lt; 0.05; Q4 vs. Q1); +10.7, +9.7, +9.2, and +7.7 letters for IAI 2q4; and +11.3, +11.2, +8.6, and +6.3 letters for IAI 2q8 (nominal <em>P</em> &lt; 0.05; Q4 vs. Q1), respectively.</div></div><div><h3>Conclusions</h3><div>Increasing duration of IRF exposure was associated with lower visual gains and less improvement in vision-related quality of life in patients with nAMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages 618-624"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Griffin et al.: Pneumatic retinopexy for rhegmatogenous retinal detachment outcomes: IRIS Registry (Intelligent Research in Sight) analysis (Ophthalmol Retina. 2025;9:437-443)","authors":"Andrew Mihalache MD(C) ,&nbsp;Marko M. Popovic MD, MPH ,&nbsp;Rajeev H. Muni MD, MSc","doi":"10.1016/j.oret.2025.04.010","DOIUrl":"10.1016/j.oret.2025.04.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages e61-e62"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of a Complicated Case of Retained Subfoveal Perfluorocarbon","authors":"Marina Roizenblatt MD, PhD ,&nbsp;Luiz Filipe Adami Lucatto MD, PhD ,&nbsp;Peter Louis Gehlbach MD, PhD","doi":"10.1016/j.oret.2024.10.027","DOIUrl":"10.1016/j.oret.2024.10.027","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Page e68"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmic Manifestations in a Diverse Pediatric Population with Type I and Type II Stickler Syndrome","authors":"Andy Drackley MS ,&nbsp;Hantamalala Ralay Ranaivo PhD ,&nbsp;Valerie Allegretti MS ,&nbsp;Alexander Y. Ing MS ,&nbsp;Safa Rahmani MD ,&nbsp;Michael P. Blair MD ,&nbsp;Michael J. Shapiro MD ,&nbsp;Brenda L. Bohnsack MD, PhD ,&nbsp;Jennifer L. Rossen MD","doi":"10.1016/j.oret.2024.12.014","DOIUrl":"10.1016/j.oret.2024.12.014","url":null,"abstract":"<div><h3>Objective</h3><div>To characterize and compare our cohorts of pediatric patients with types I and II Stickler syndrome, with a focus on ophthalmic features.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Twenty-six patients (22 families) with clinical and genetic diagnoses of type I or II Stickler syndrome.</div></div><div><h3>Methods</h3><div>Review of clinical notes and molecular diagnoses.</div></div><div><h3>Main Outcome Measures</h3><div>Ophthalmic and systemic features and responses to laser treatment.</div></div><div><h3>Results</h3><div>Our cohorts had an equal number of patients with <em>COL2A1</em>-related/type I and <em>COL11A1</em>-related/type II Stickler syndrome (n = 13; 50%) and included 12 previously unpublished variants. Patients in type I and II cohorts had similar average ages at presentation and length of follow-up. There were more self-identifying Hispanic patients among the type II cohort than type I (69% vs. 39%, <em>P</em> = 0.145). Individuals with type II on average had significantly higher myopia compared with those with type I (<em>P</em> = 0.008). Retinal detachment (RD) in at least 1 eye was diagnosed in 39% of the type I cohort (7 eyes, 5 patients) and 46% of the type II (7 eyes, 6 patients). Laser prophylaxis was used in 69% of patients with type I and 85% with type II. Unilateral RD after laser prophylaxis occurred in 1 patient with type I and 2 with type II. All identified <em>COL2A1</em> variants in the type I cohort are expected to cause disease through haploinsufficiency, and 92% of <em>COL11A1</em> variants in the type II cohort are presumed to be in-frame and exert a dominant-negative effect, consistent with historical reporting.</div></div><div><h3>Conclusions</h3><div>The proportion of types I and II Stickler syndrome are equal in our pediatric population, and patients self-identifying as Hispanic comprised the majority of type II, supporting the need for additional study of possible underdetection of type II in diverse populations. Our type II cohort showed higher myopia and incidence of Pierre Robin sequence, and similar rates of RD and systemic manifestations compared with the type I cohort. Our data sets provide important data regarding the safety and short-term effectiveness of laser prophylaxis, but larger and longer-term studies are needed, especially for those with type II Stickler syndrome.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages 690-698"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macular Atrophy in Neovascular Age-related Macular Degeneration","authors":"Alessandro Berni MD ,&nbsp;Andrea Coletto MD ,&nbsp;Jianqing Li MD ,&nbsp;Mengxi Shen MD, PhD ,&nbsp;Francesco Bandello MD ,&nbsp;Michele Reibaldi MD, PhD ,&nbsp;Enrico Borrelli MD, PhD","doi":"10.1016/j.oret.2025.01.011","DOIUrl":"10.1016/j.oret.2025.01.011","url":null,"abstract":"<div><h3>Topic</h3><div>Macular atrophy incidence in neovascular age-related macular degeneration (AMD) patients undergoing anti-VEGF treatment.</div></div><div><h3>Clinical Relevance</h3><div>Macular atrophy is a significant event that may occur in eyes with neovascular AMD treated with anti-VEGF therapy.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis following PRISMA guidelines (PROSPERO, CRD42024474924). A comprehensive literature search of MEDLINE, EMBASE, and Web of Science was performed up to November 1, 2023. Randomized and nonrandomized studies of treatment-naive neovascular AMD patients reporting macular atrophy incidence at 24 ± 3 months after anti-VEGF therapy were eligible. Two independent reviewers conducted screening, data extraction, and quality assessment. For randomized controlled trials, the Cochrane Risk of Bias 2 tool was employed, whereas nonrandomized studies were evaluated using the Risk Of Bias In Nonrandomized Studies of Interventions tool. Random-effects meta-analysis models accounted for study variability. Heterogeneity was assessed with the <em>I</em>² statistic, and publication bias by funnel plots and Egger test. The primary outcome was the incidence of new macular atrophy at 24 months post-treatment, with secondary outcomes at 12 months. Atrophy was diagnosed using color fundus photograph, fluorescein angiography, fundus autofluorescence, OCT, or multimodal imaging.</div></div><div><h3>Results</h3><div>Twenty-three studies met the inclusion criteria for qualitative analysis, with 11 included in the meta-analysis (N = 3013 eyes). The pooled 24-month incidence of macular atrophy was 29% (95% confidence interval [CI]: 20%–38%, <em>I</em>² = 93%). Subgroup analysis revealed incidence rates of 26% (95% CI: 15%–37%, <em>I</em>² = 88%) for 814 eyes with type 1/2 macular neovascularization (MNV), 49% (95% CI: 18%–80%, <em>I</em>² = 92%) for type 3 MNV (N = 230 eyes), and 29% (95% CI: 18%–40%, <em>I</em>² = 96%) for all MNV types (N = 2131 eyes). The pooled 12-month incidence among 2214 eyes was 11% (95% CI: 4%–18%, <em>I</em>² = 93%). The certainty of evidence, as assessed by Grading of Recommendations, Assessment, Development and Evaluation, was low.</div></div><div><h3>Conclusion</h3><div>Although this meta-analysis has limitations, including a moderate risk of bias in nonrandomized studies, inconsistencies in the results indicated by high heterogeneity, and imprecision due to the different imaging modalities used to diagnose macular atrophy, our results suggest that macular atrophy could be a common complication in patients with neovascular AMD receiving anti-VEGF therapy.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages 625-644"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal Nevus with Mega Druse","authors":"Dishaa Ramesh BS,&nbsp;Roger A. Goldberg MD, MBA","doi":"10.1016/j.oret.2024.11.016","DOIUrl":"10.1016/j.oret.2024.11.016","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Page e74"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Tsai et al.: Clinical characteristics and treatment outcomes in unilateral Coats disease: a global collaborative study (Ophthalmol Retina. 2025;9:570-579)","authors":"Saarang Hansraj MS ,&nbsp;Vishal Raval MD","doi":"10.1016/j.oret.2025.04.008","DOIUrl":"10.1016/j.oret.2025.04.008","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages e64-e65"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foveal Avascular Zone Enlargement Correlates with Visual Acuity Decline in Patients with Diabetic Retinopathy","authors":"Brandon V. Duffy BS ,&nbsp;Daniela Castellanos-Canales MD ,&nbsp;Nicole L. Decker BS ,&nbsp;Hunter Jung-ah Lee ,&nbsp;Taffeta C. Yamaguchi MS ,&nbsp;Elizabeth Pearce MD ,&nbsp;Amani A. Fawzi MD","doi":"10.1016/j.oret.2024.12.015","DOIUrl":"10.1016/j.oret.2024.12.015","url":null,"abstract":"<div><h3>Purpose</h3><div>The foveal avascular zone (FAZ) area has been explored as a measure of macular ischemia in diabetic retinopathy (DR) but is limited by its wide variability even in healthy individuals. We hypothesized that FAZ enlargement, defined as the difference between the functional FAZ (on OCT angiography [OCTA]) and structural FAZ (on en face OCT), may be a more accurate metric of macular ischemia. In this study, we test the hypothesis that FAZ enlargement is associated with decreased best-corrected visual acuity (BCVA) and low-luminance visual acuity (LLVA) and performs better than the functional FAZ as a marker of vision loss.</div></div><div><h3>Design</h3><div>Cross-sectional study.</div></div><div><h3>Subjects</h3><div>Patients with diabetes mellitus (DM) and a wide range of DR severity.</div></div><div><h3>Methods</h3><div>For 264 eyes from 174 patients, we measured BCVA and LLVA using ETDRS letter scores. Averaged en face OCT and OCTA scans identified structural and functional FAZ areas, respectively. Spearman’s ρ quantified relationships between FAZ enlargement and visual acuity, which were further assessed with linear mixed-effects models that accounted for potential confounders, which were identified using univariate analysis.</div></div><div><h3>Main Outcome Measures</h3><div>Relationship between FAZ enlargement (or functional FAZ area) and visual function.</div></div><div><h3>Results</h3><div>Age, axial length, lens status (phakic or pseudophakic), hypertensive status, ischemic heart disease, cerebrovascular disease, renal disease, dyslipidemia, DR severity, and functional FAZ area correlated with BCVA on univariate analysis. Age, body mass index, hypertension, ischemic heart disease, renal disease, dyslipidemia, smoking status, DR severity, and functional FAZ area correlated with LLVA on univariate analysis. Foveal avascular zone enlargement demonstrated a weak negative correlation with BCVA (ρ = −0.364, <em>P</em> &lt; 0.001) and LLVA (ρ = −0.306, <em>P</em> &lt; 0.001), which remained significant in mixed-effects regression analysis. Functional FAZ area was not a significant predictor of BCVA or LLVA in models where FAZ enlargement was also included as a predictor. Model comparison using analysis of variance indicated that inclusion of FAZ enlargement improved the prediction of BCVA (chi-square = 5.62, <em>P</em> = 0.018) and LLVA (chi-square = 4.99, <em>P</em> = 0.025).</div></div><div><h3>Conclusions</h3><div>Foveal avascular zone enlargement performed better than the functional FAZ providing an improved imaging metric of the influence of foveal ischemia on vision impairment in DR.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 7","pages":"Pages 667-676"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}